Literature DB >> 29170879

Factors influencing recurrence and progression of Dupuytren's disease treated by Collagenase Clostridium histolitycum.

Clarisa Simón-Pérez1, Julian Alía-Ortega2, Belen García-Medrano2, Jose Ignacio Rodríguez-Mateos2, Maria Brotat-Rodríguez2, Hector Aguado-Hernandez2, Miguel Angel Martín-Ferrero2.   

Abstract

AIM OF THE STUDY: The purpose of this study was to determine the recurrence rate, possible adverse reactions and factors influencing recurrence and progression of Dupuytren's disease (DD) treated with Collagenase from Clostridium histolyticum (CCH).
METHOD: This was a prospective study of 71 patients with DD treated with CCH from 2011 to February 2013, with a minimum follow-up period of four years. Clinical, functional, patient satisfaction, drug safety and factors influencing recurrence and disease progression were evaluated.
RESULTS: In all patients, the rupture of the cord was achieved after the injection, reducing joint contracture. In five patients (7%) we verified the existence of disease recurrence during the follow-up. In 11 patients (15.5%) there was a disease progression. Three patients have been surgically operated on, without added surgery difficulty; the rate of recurrence and progression was higher in grades III and IV of Tubiana, in proximal interphalangeal (PIP) punctures, and was earlier in patients younger than 60 years. DISCUSSION: No serious local complications or general complications were observed with this method. The recurrence of DD, following criteria of Felici, is mainly observed in young patients with greater severity of the disease and at the PIP level. Progression is influenced by the same factors. Patients operated on after recurrence have no added difficulty in the surgical technique, as it has also been published in other studies.
CONCLUSIONS: Patients with the lowest rates of recurrence and progression were those with a single cord in the metacarpophalangeal (MCP), a grade II of Tubiana, and were older than 60 years.

Entities:  

Keywords:  Collagenase Clostridium histolitycum; Dupuytren’s disease; Recurrence and progression

Mesh:

Substances:

Year:  2017        PMID: 29170879     DOI: 10.1007/s00264-017-3690-0

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  16 in total

1.  Skin laceration as a serious adverse sequela of injectable collagenase for Dupuytren contracture.

Authors:  Geoffrey G Hallock
Journal:  Plast Reconstr Surg       Date:  2012-01       Impact factor: 4.730

2.  Cost-effectiveness of open partial fasciectomy, needle aponeurotomy, and collagenase injection for dupuytren contracture.

Authors:  Neal C Chen; Melissa J Shauver; Kevin C Chung
Journal:  J Hand Surg Am       Date:  2011-10-05       Impact factor: 2.230

3.  Flexor tendon rupture after collagenase injection for Dupuytren contracture: case report.

Authors:  Andrew Y Zhang; Catherine M Curtin; Vincent R Hentz
Journal:  J Hand Surg Am       Date:  2011-06-25       Impact factor: 2.230

Review 4.  The treatment of Dupuytren disease.

Authors:  Shaunak S Desai; Vincent R Hentz
Journal:  J Hand Surg Am       Date:  2011-05       Impact factor: 2.230

5.  Salvage palmar fasciectomy after initial treatment with collagenase clostridium histolyticum.

Authors:  Kyle R Eberlin; Edward M Kobraei; Theodore T Nyame; Jacob M Bloom; Joseph Upton
Journal:  Plast Reconstr Surg       Date:  2015-06       Impact factor: 4.730

Review 6.  Skin graft loss resulting from collagenase clostridium histolyticum treatment of Dupuytren contracture: case report and review of the literature.

Authors:  Jordan W Swanson; Andrew J Watt; Nicholas B Vedder
Journal:  J Hand Surg Am       Date:  2013-02-05       Impact factor: 2.230

7.  Surgical findings in the treatment of Dupuytren's disease after initial treatment with clostridial collagenase (Xiaflex).

Authors:  D C Hay; D L Louie; B E Earp; F T D Kaplan; E Akelman; P E Blazar
Journal:  J Hand Surg Eur Vol       Date:  2013-05-06

8.  Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren's disease.

Authors:  David Gilpin; Stephen Coleman; Stephen Hall; Anthony Houston; Jeff Karrasch; Nigel Jones
Journal:  J Hand Surg Am       Date:  2010-12       Impact factor: 2.230

9.  Dupuytren contracture recurrence project: reaching consensus on a definition of recurrence.

Authors:  N Felici; I Marcoccio; R Giunta; M Haerle; C Leclercq; G Pajardi; S Wilbrand; A V Georgescu; G Pess
Journal:  Handchir Mikrochir Plast Chir       Date:  2014-11-20       Impact factor: 1.018

10.  Efficacy of collagenase in patients who did and did not have previous hand surgery for Dupuytren's contracture.

Authors:  Chris Bainbridge; Robert A Gerber; Piotr P Szczypa; Ted Smith; Harvey Kushner; Brian Cohen; Marie-Pierre Hellio Le Graverand-Gastineau
Journal:  J Plast Surg Hand Surg       Date:  2012-06-07
View more
  3 in total

1.  Seven-year clinical outcomes after collagenase injection in patients with Dupuytren's disease: A prospective study.

Authors:  Rocco De Vitis; Marco Passiatore; Andrea Perna; Silvia Careri; Vitale Cilli; Giuseppe Taccardo
Journal:  J Orthop       Date:  2020-03-29

2.  Treatment of Dupuytren's Contracture With Collagenase: A Systematic Review.

Authors:  Alexis B Sandler; John P Scanaliato; Thomas Dennis; Gilberto A Gonzalez Trevizo; Sorana Raiciulescu; Leon Nesti; John C Dunn
Journal:  Hand (N Y)       Date:  2021-01-21

3.  Cost-effectiveness of Recurrent Dupuytren Contracture Treatment.

Authors:  Alfred P Yoon; Robert L Kane; David W Hutton; Kevin C Chung
Journal:  JAMA Netw Open       Date:  2020-10-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.